+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Cell & Gene Therapy Manufacturing Services Market by Service Type (Analytical & Quality Control Services, Cell Banking Services, Consulting Services), Technology Type (Gene Editing, Vectors), Therapeutic Area, Application, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5591961
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Cell & Gene Therapy Manufacturing Services Market grew from USD 19.98 billion in 2024 to USD 23.06 billion in 2025. It is expected to continue growing at a CAGR of 15.90%, reaching USD 48.44 billion by 2030.

Introduction to the Evolving Cell and Gene Therapy Manufacturing Landscape Highlighting Key Drivers, Innovations, and Strategic Imperatives for Stakeholders

The cell and gene therapy manufacturing sector is undergoing a period of extraordinary transformation as scientific innovation converges with evolving regulatory frameworks and growing market demand. Stakeholders across contract development, clinical supply, and commercial production are navigating an increasingly complex environment characterized by stringent quality standards and the need for scalable, cost-effective processes. Against this backdrop, this executive summary presents a concise yet comprehensive introduction to the forces shaping the industry’s trajectory and the strategic imperatives that will define competitiveness in the coming years.

As the pace of therapeutic approvals accelerates, manufacturers face rising expectations for agile production platforms, robust supply chains, and advanced analytics that can deliver reproducible, patient-ready therapies at commercial scale. This summary lays the groundwork for understanding key market drivers, emerging technologies, and the partnerships necessary to translate scientific breakthroughs into reliable, compliant, and economically sustainable manufacturing operations.

Examining the Transformative Technological, Regulatory, and Commercial Shifts Reshaping Cell and Gene Therapy Manufacturing Across the Globe

Recent years have witnessed fundamental shifts across technological, regulatory, and commercial domains that are redefining the capabilities of cell and gene therapy production. Advanced vector design and automated bioreactor systems are converging to shorten development timelines, while single-use technologies and modular facility footprints offer unprecedented flexibility in scaling capacity. Meanwhile, regulatory authorities are harmonizing standards and introducing accelerated pathways, prompting manufacturers to enhance traceability and real-time monitoring practices.

In parallel, commercial dynamics are reshaping partnerships and investment models. Collaborative alliances between biotech innovators and specialized contract development and manufacturing organizations are becoming the norm, driven by a shared imperative to balance cost control with stringent quality requirements. Supply chain resilience has also emerged as a critical priority, leading to geographically distributed networks that mitigate disruption risks. Taken together, these transformative trends underscore a paradigm shift in which agility, digital integration, and strategic collaboration are essential to capturing value and ensuring patient access.

Assessing the Comprehensive Implications of the 2025 United States Tariffs on Cell and Gene Therapy Manufacturing Supply Chains, Costs, and Competitiveness

The introduction of new United States tariffs in 2025 has instigated a reevaluation of cross-border supply chains, material sourcing strategies, and cost structures across the cell and gene therapy manufacturing ecosystem. Components for viral vector production, single-use assemblies, and critical reagents now face elevated duties, prompting organizations to reassess their supplier portfolios and logistical pathways. As a result, some manufacturers are shifting non-core activities to domestic or near-shore providers to attenuate the impact of increased import costs.

Moreover, these cumulative trade measures have catalyzed a broader dialogue on vertical integration and localized manufacturing hubs. By investing in domestic fill-and-finish capabilities and establishing regional vector production sites, stakeholders can insulate operations from tariff volatility while fostering closer alignment with regulatory inspection regimes. At the same time, collaborative purchasing consortia are emerging to leverage aggregated volumes and negotiate preferential terms. Through these adaptive strategies, the industry is demonstrating a pragmatic response to policy-driven headwinds and reinforcing its commitment to uninterrupted patient supply.

Unveiling Critical Market Segmentation Insights Across Service Types, Technology Platforms, Therapeutic Areas, Applications, and End Users in Manufacturing Ecosystems

An in-depth examination of market segmentation reveals nuanced dynamics across service offerings, technology platforms, therapeutic focus areas, application stages, and end-user profiles. Within service types, analytical and quality control, cell banking, consulting, fill and finish, GMP manufacturing, process development, regulatory support, supply chain and logistics, technology transfer, and vector production services each serve distinct roles in de-risking scale-up and ensuring compliance. Simultaneously, the bifurcation between gene editing and vector design introduces further granularity: gene editing modalities such as CRISPR/Cas9, transcription activator-like effector nucleases, and zinc finger nucleases are matched by viral vector approaches like adeno-associated virus, adenovirus, herpes simplex virus, and retrovirus alongside a broad spectrum of non-viral platforms including liposomes, dendrimers, and peptide-based carriers.

Therapeutic areas spanning cardiovascular diseases, infectious diseases, monogenic disorders, and oncology steer production priorities toward specific capacity needs, whether for heart failure vectors or gene-corrected hemoglobin therapies. Applications range from early-phase clinical manufacturing to full commercialization, each stage imposing unique process validation and tech transfer challenges. Finally, the end-user landscape encompasses contract research organizations, hospitals and clinics, pharmaceutical and biotech companies, and research institutes and academic settings, collectively driving demand for tailored manufacturing strategies and responsive service models.

Regional Perspectives on Cell and Gene Therapy Manufacturing Highlighting the Distinct Dynamics Across Americas, EMEA, and Asia-Pacific Markets

Diverse regional market dynamics are influencing strategic decisions as manufacturers pursue both operational excellence and risk mitigation. In the Americas, a robust network of specialized CDMOs, coupled with progressive regulatory pathways, fosters rapid technology adoption and substantial private investment. Given the concentration of pioneering clinical trials and commercial launches, North American facilities are increasingly equipped with advanced analytics and automation tools, reinforcing their leadership in high-complexity cell and gene therapies.

By contrast, Europe, the Middle East and Africa present a mosaic of regulatory frameworks that reward early engagement and joint assessment procedures, prompting manufacturers to establish regional centers of excellence and collaborative manufacturing consortia. These networks leverage shared infrastructure to streamline capacity expansion while addressing localized requirements. Meanwhile, the Asia-Pacific region is emerging as a competitive manufacturing hub, underpinned by supportive government initiatives, favorable production costs, and rapid infrastructure development. Countries across the region are investing in bioprocessing clusters, workforce training, and digital platforms to enhance supply chain connectivity and meet growing domestic demand.

Insights into Leading Contract Development and Manufacturing Organizations and Strategic Partnerships Driving Innovation in Cell and Gene Therapy Production

A select group of leading contract development and manufacturing organizations is defining best practices for cell and gene therapy production through strategic investments, collaborative alliances, and technology integration. These companies are expanding cleanroom capacity with modular, single-use facilities designed for rapid repurposing between clinical and commercial workflows. In parallel, they are integrating digital twin simulations and real-time monitoring systems to improve process consistency and accelerate regulatory submissions.

Furthermore, partnerships between these CDMOs and academic research centers are fostering early-stage innovation in vector design and cell line development, effectively de-risking scale-up challenges. By combining deep bioprocess expertise with advanced analytics and risk-based quality control frameworks, these organizations are creating vertically integrated service models that streamline timelines and lower barriers to entry. Their collective focus on supply chain resilience-through redundant sourcing strategies and strategic geographic footprint optimization-has become a blueprint for operational robustness in a rapidly evolving market.

Actionable Strategic Recommendations for Industry Leaders to Navigate Regulatory Complexities, Optimize Supply Chains, and Accelerate Manufacturing Excellence

Industry leaders can capitalize on emerging opportunities by adopting a proactive, multifaceted strategy that addresses regulatory complexity, technological advancements, and evolving market demands. First, creating modular manufacturing platforms with built-in flexibility allows rapid scaling and adaptive use of single-use and continuous bioprocessing technologies. This approach reduces capital expenditure cycles and accelerates time to market.

Next, investing in integrated data ecosystems and artificial intelligence-driven analytics will enhance process robustness and facilitate real-time quality monitoring. Concurrently, fostering early collaboration with regulatory authorities-through joint scientific advice and rolling review initiatives-will streamline approval pathways and ensure alignment on evolving standards. Finally, diversifying supply chains by forging partnerships with regional providers and leveraging contract manufacturing networks will mitigate geopolitical and tariff-related risks. By executing this comprehensive roadmap, leaders will reinforce resilience, drive cost efficiencies, and maintain a decisive competitive edge.

Detailed Research Methodology Outlining Data Collection, Analysis Techniques, and Validation Processes Underpinning the Cell and Gene Therapy Manufacturing Study

This research study integrates multiple data sources and analytical frameworks to ensure rigorous, transparent, and defensible insights. Primary data was gathered through in-depth interviews with senior executives, process engineers, and quality assurance specialists across leading manufacturing facilities. These engagements provided firsthand perspectives on operational challenges, technology adoption timelines, and strategic investment priorities.

Complementing primary research, secondary data was sourced from peer-reviewed journals, regulatory filings, and publicly available industry reports. Quantitative data underwent triangulation through cross-referencing supplier disclosures, patent landscapes, and clinical trial registries, ensuring consistency and validation. Analytical techniques such as scenario modeling, sensitivity analysis, and value chain mapping were applied to assess tariff impacts, technology diffusion, and segmentation performance. Finally, all findings were subjected to a multi-layered quality control process, including expert panel reviews and editorial oversight, to maintain the highest standards of accuracy and objectivity.

Conclusive Reflections on the Future of Cell and Gene Therapy Manufacturing Emphasizing Strategic Imperatives and Industry Resilience Strategies

In closing, the cell and gene therapy manufacturing sector stands at a pivotal juncture where scientific promise must be matched by manufacturing innovation and strategic foresight. The intersection of advanced vector platforms, automated bioprocessing, and data-driven quality frameworks is creating a new paradigm of agile, compliant, and cost-effective production.

Looking ahead, organizations that embrace modular facility design, integrated digital ecosystems, and collaborative regulatory engagement will be best positioned to deliver life-changing therapies at scale. By maintaining a focus on supply chain resilience and leveraging specialized partnerships, stakeholders can mitigate external challenges and accelerate patient access. Ultimately, the sustained growth and global impact of cell and gene therapies will depend on the industry’s ability to harmonize innovation with operational excellence and strategic alignment.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Service Type
    • Analytical & Quality Control Services
    • Cell Banking Services
    • Consulting Services
    • Fill & Finish Services
    • GMP Manufacturing Services
    • Process Development Services
    • Regulatory Support Services
    • Supply Chain & Logistics Services
    • Technology Transfer Services
    • Vector Production Services
  • Technology Type
    • Gene Editing
      • CRISPR/Cas9
      • Transcription Activator-Like Effector Nucleases
      • Zinc Finger Nucleases
    • Vectors
      • Non-Viral Vectors
        • Cationic Lipids
        • Chitosan-Based Vectors
        • Dendrimers
        • Inorganic Nanoparticles
        • Liposomes
        • Naked DNA/RNA
        • Peptide-Based Vectors
        • Polymeric Vectors
      • Viral Vectors
        • Adeno-Associated Virus (AAV) Vectors
        • Adenovirus Vectors
        • Herpes Simplex Virus (HSV) Vectors
        • Retrovirus Vectors
  • Therapeutic Area
    • Cardiovascular Diseases
      • Coronary Artery Disease
      • Heart Failure
    • Infectious Diseases
      • Hepatitis B
      • HIV
    • Monogenic Disorders
      • Cystic Fibrosis
      • Hemophilia
      • Sickle Cell Anemia
    • Oncology
      • Hematological Malignancies
      • Solid Tumors
  • Application
    • Clinical Manufacturing
    • Commercial Manufacturing
  • End-User
    • Contract Research Organizations
    • Hospitals & Clinics
    • Pharmaceutical & Biotech Companies
    • Research Institutes & Academic Institutions
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Advanced BioScience Laboratories, Inc. by Institut Mérieux
  • AGC Biologics
  • AmplifyBio
  • Bio-Techne Corporation
  • C.H. Boehringer Sohn AG & Co. KG
  • Catalent, Inc.
  • Cell Therapies Pty Ltd.
  • Cell-Easy
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • eXmoor Pharma Concepts Limited
  • FUJIFILM Diosynth Biotechnologies
  • Genezen Laboratories, Inc.
  • Laboratory Corporation of America Holdings
  • Lonza Group AG
  • Merck KGaA
  • Miltenyi Biotec B.V. & Co. KG
  • Minaris Regenerative Medicine GmbH by Resonac Corporation
  • Nikon Corporation
  • Novartis AG
  • Oxford Biomedica PLC
  • ProPharma Group Holdings, LLC
  • Recipharm AB
  • Samsung Biologics Co., Ltd.
  • SGS S.A.
  • STEMCELL Technologies Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • uBriGene Biosciences Inc.
  • WuXi AppTec Co., Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of closed automated bioreactor systems for large-scale CAR-T production to enhance reproducibility
5.2. Implementation of digital twin and process analytical technology for real-time monitoring of gene therapy manufacturing
5.3. Expansion of decentralized manufacturing networks using modular GMP suites to accelerate regional clinical supply
5.4. Standardization of raw material quality and supply chain traceability for viral vector and cell substrate components
5.5. Adoption of single-use manufacturing platforms to minimize cross-contamination and improve facility flexibility
5.6. Collaboration between CDMOs and academic centers for development of off-the-shelf allogeneic cell therapy pipelines
5.7. Regulatory harmonization efforts addressing potency assays and comparability for advanced therapy medicinal products
5.8. Investment in advanced viral vector purification technologies to increase yield and reduce downstream bottlenecks
5.9. Use of AI-driven process optimization for predictive maintenance and yield improvement in cell and gene therapy manufacturing
5.10. Development of cryopreservation protocols and supply chain logistics to support global distribution of living cell therapeutics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cell & Gene Therapy Manufacturing Services Market, by Service Type
8.1. Introduction
8.2. Analytical & Quality Control Services
8.3. Cell Banking Services
8.4. Consulting Services
8.5. Fill & Finish Services
8.6. GMP Manufacturing Services
8.7. Process Development Services
8.8. Regulatory Support Services
8.9. Supply Chain & Logistics Services
8.10. Technology Transfer Services
8.11. Vector Production Services
9. Cell & Gene Therapy Manufacturing Services Market, by Technology Type
9.1. Introduction
9.2. Gene Editing
9.2.1. CRISPR/Cas9
9.2.2. Transcription Activator-Like Effector Nucleases
9.2.3. Zinc Finger Nucleases
9.3. Vectors
9.3.1. Non-Viral Vectors
9.3.1.1. Cationic Lipids
9.3.1.2. Chitosan-Based Vectors
9.3.1.3. Dendrimers
9.3.1.4. Inorganic Nanoparticles
9.3.1.5. Liposomes
9.3.1.6. Naked DNA/RNA
9.3.1.7. Peptide-Based Vectors
9.3.1.8. Polymeric Vectors
9.3.2. Viral Vectors
9.3.2.1. Adeno-Associated Virus (AAV) Vectors
9.3.2.2. Adenovirus Vectors
9.3.2.3. Herpes Simplex Virus (HSV) Vectors
9.3.2.4. Retrovirus Vectors
10. Cell & Gene Therapy Manufacturing Services Market, by Therapeutic Area
10.1. Introduction
10.2. Cardiovascular Diseases
10.2.1. Coronary Artery Disease
10.2.2. Heart Failure
10.3. Infectious Diseases
10.3.1. Hepatitis B
10.3.2. HIV
10.4. Monogenic Disorders
10.4.1. Cystic Fibrosis
10.4.2. Hemophilia
10.4.3. Sickle Cell Anemia
10.5. Oncology
10.5.1. Hematological Malignancies
10.5.2. Solid Tumors
11. Cell & Gene Therapy Manufacturing Services Market, by Application
11.1. Introduction
11.2. Clinical Manufacturing
11.3. Commercial Manufacturing
12. Cell & Gene Therapy Manufacturing Services Market, by End-User
12.1. Introduction
12.2. Contract Research Organizations
12.3. Hospitals & Clinics
12.4. Pharmaceutical & Biotech Companies
12.5. Research Institutes & Academic Institutions
13. Americas Cell & Gene Therapy Manufacturing Services Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Cell & Gene Therapy Manufacturing Services Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Cell & Gene Therapy Manufacturing Services Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Advanced BioScience Laboratories, Inc. by Institut Mérieux
16.3.2. AGC Biologics
16.3.3. AmplifyBio
16.3.4. Bio-Techne Corporation
16.3.5. C.H. Boehringer Sohn AG & Co. KG
16.3.6. Catalent, Inc.
16.3.7. Cell Therapies Pty Ltd.
16.3.8. Cell-Easy
16.3.9. Charles River Laboratories International, Inc.
16.3.10. Danaher Corporation
16.3.11. eXmoor Pharma Concepts Limited
16.3.12. FUJIFILM Diosynth Biotechnologies
16.3.13. Genezen Laboratories, Inc.
16.3.14. Laboratory Corporation of America Holdings
16.3.15. Lonza Group AG
16.3.16. Merck KGaA
16.3.17. Miltenyi Biotec B.V. & Co. KG
16.3.18. Minaris Regenerative Medicine GmbH by Resonac Corporation
16.3.19. Nikon Corporation
16.3.20. Novartis AG
16.3.21. Oxford Biomedica PLC
16.3.22. ProPharma Group Holdings, LLC
16.3.23. Recipharm AB
16.3.24. Samsung Biologics Co., Ltd.
16.3.25. SGS S.A.
16.3.26. STEMCELL Technologies Inc.
16.3.27. Takara Bio Inc.
16.3.28. Thermo Fisher Scientific Inc.
16.3.29. uBriGene Biosciences Inc.
16.3.30. WuXi AppTec Co., Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: RESEARCHAI
FIGURE 26. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: RESEARCHSTATISTICS
FIGURE 27. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: RESEARCHCONTACTS
FIGURE 28. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL BANKING SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL BANKING SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY FILL & FINISH SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY FILL & FINISH SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGULATORY SUPPORT SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGULATORY SUPPORT SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TRANSFER SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TRANSFER SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTOR PRODUCTION SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTOR PRODUCTION SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CRISPR/CAS9, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CRISPR/CAS9, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CATIONIC LIPIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CATIONIC LIPIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CHITOSAN-BASED VECTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CHITOSAN-BASED VECTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DENDRIMERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INORGANIC NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INORGANIC NANOPARTICLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY LIPOSOMES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NAKED DNA/RNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NAKED DNA/RNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PEPTIDE-BASED VECTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PEPTIDE-BASED VECTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY POLYMERIC VECTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY POLYMERIC VECTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENOVIRUS VECTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENOVIRUS VECTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRUS VECTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRUS VECTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEART FAILURE, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HIV, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMOPHILIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SICKLE CELL ANEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SICKLE CELL ANEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RESEARCH INSTITUTES & ACADEMIC INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RESEARCH INSTITUTES & ACADEMIC INSTITUTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 187. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 188. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 189. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
TABLE 190. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2030 (USD MILLION)
TABLE 191. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
TABLE 192. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
TABLE 193. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2024 (USD MILLION)
TABLE 194. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2025-2030 (USD MILLION)
TABLE 195. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 196. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 197. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 198. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 199. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 200. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 201. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 202. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 203. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 204. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 205. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 206. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 207. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 208. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 209. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 210. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 211. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 212. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 213. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 214. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 215. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
TABLE 216. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2030 (USD MILLION)
TABLE 217. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
TABLE 218. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
TABLE 219. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2024 (USD MILLION)
TABLE 220. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2025-2030 (USD MILLION)
TABLE 221. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 222. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 223. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 224. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 225. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 226. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 227. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 228. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 229. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 230. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 231. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 232. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 233. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 234. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 235. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 236. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 237. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 238. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 239. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 240. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 241. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
TABLE 242. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2030 (USD MILLION)
TABLE 243. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
TABLE 244. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 249. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
TABLE 250. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2025-2030 (USD MILLION)
TABLE 251. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 252. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 253. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 254. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 255. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 256. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 257. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 258. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 259. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 260. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 261. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 262. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 263. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 264. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 265. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 266. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MI

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Cell & Gene Therapy Manufacturing Services market report include:
  • Advanced BioScience Laboratories, Inc. by Institut Mérieux
  • AGC Biologics
  • AmplifyBio
  • Bio-Techne Corporation
  • C.H. Boehringer Sohn AG & Co. KG
  • Catalent, Inc.
  • Cell Therapies Pty Ltd.
  • Cell-Easy
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • eXmoor Pharma Concepts Limited
  • FUJIFILM Diosynth Biotechnologies
  • Genezen Laboratories, Inc.
  • Laboratory Corporation of America Holdings
  • Lonza Group AG
  • Merck KGaA
  • Miltenyi Biotec B.V. & Co. KG
  • Minaris Regenerative Medicine GmbH by Resonac Corporation
  • Nikon Corporation
  • Novartis AG
  • Oxford Biomedica PLC
  • ProPharma Group Holdings, LLC
  • Recipharm AB
  • Samsung Biologics Co., Ltd.
  • SGS S.A.
  • STEMCELL Technologies Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • uBriGene Biosciences Inc.
  • WuXi AppTec Co., Ltd.

Table Information